| Literature DB >> 22740451 |
Luca Agnelli1, Elisabetta Mereu, Elisa Pellegrino, Tania Limongi, Ivo Kwee, Elisa Bergaggio, Maurilio Ponzoni, Alberto Zamò, Javeed Iqbal, Pier Paolo Piccaluga, Antonino Neri, Wing C Chan, Stefano Pileri, Francesco Bertoni, Giorgio Inghirami, Roberto Piva.
Abstract
Anaplastic large-cell lymphomas (ALCLs) are a group of clinically and biologically heterogeneous diseases including the ALK(+) and ALK(-) systemic forms. Whereas ALK(+) ALCLs are molecularly characterized and can be readily diagnosed, specific immunophenotypic or genetic features to define ALK(-) ALCL are missing, and their distinction from other T-cell non-Hodgkin lymphomas (T-NHLs) remains controversial. In the present study, we undertook a transcriptional profiling meta-analysis of 309 cases, including ALCL and other primary T-NHL samples. Pathway discovery and prediction analyses defined a minimum set of genes capable of recognizing ALK(-) ALCL. Application of quantitative RT-PCR in independent datasets from cryopreserved and formalin-fixed paraffin-embedded samples validated a 3-gene model (TNFRSF8, BATF3, and TMOD1) able to successfully separate ALK(-) ALCL from peripheral T-cell lymphoma not otherwise specified, with overall accuracy near 97%. In conclusion, our data justify the possibility of translating quantitative RT-PCR protocols to routine clinical settings as a new approach to objectively dissect T-NHL and to select more appropriate therapeutic protocols.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22740451 DOI: 10.1182/blood-2012-01-405555
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113